Capricor Therapeutics (CAPR) Stock Price, News & Analysis

Company Overview

Capricor Therapeutics, Inc. is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company’s research is based on technologies intended to modulate inflammation, fibrosis and tissue damage, with an emphasis on rare and degenerative conditions.

Capricor’s lead investigational product is deramiocel, formerly known as CAP-1002. It is an allogeneic cell therapy derived from cardiosphere-derived cells and is being developed for Duchenne muscular dystrophy, a progressive genetic disorder that causes muscle degeneration. The company has also developed an exosome technology platform for potential use in vaccines, therapeutics and drug delivery.

Founded in 2005 and headquartered in Beverly Hills, California, Capricor conducts its development activities primarily in the United States and works with research and industry partners as its programs advance. The company is led by Linda Marbán, Ph.D., who serves as president and chief executive officer and has been associated with the company since its formation.

Key Stats

• Today's Range: $6.68 to $7.25
• 50-Day Range: $3.85 to $10.06
• 52-Week Range: $2.96 to $40.37
• Volume: 1.92 million shs
• Average Volume: 3.73 million shs
• Market Capitalization: $390.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.25
• Consensus Rating: Hold

Capricor Therapeutics Stock Analysis - MarketRank™

Capricor Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 552nd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Hold

Consensus Rating

Capricor Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on no strong buy ratings, 4 buy ratings, 6 hold ratings, and 1 sell rating.

Upside Potential

Capricor Therapeutics has a consensus price target of $30.25, representing about 350.8% upside from its current price of $6.71.

Amount of Analyst Coverage

Capricor Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Capricor Therapeutics are expected to grow in the coming year, from ($1.71) to ($1.19) per share.

Price to Book Value per Share Ratio

Capricor Therapeutics has a P/B Ratio of 1.21. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

35.66% of the float of Capricor Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Capricor Therapeutics has a short interest ratio ("days to cover") of 4.52.

Change versus previous month

Short interest in Capricor Therapeutics has recently decreased by 4.35%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Capricor Therapeutics does not currently pay a dividend.

Dividend Growth

Capricor Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: N/A

Search Interest

32 people have searched for CAPR on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.

MarketBeat Follows

12 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.20% of the stock of Capricor Therapeutics is held by insiders.

Percentage Held by Institutions

21.68% of the stock of Capricor Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/17/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CAPR
• CIK: 1133869
• Web: www.capricor.com
• Phone: 310-358-3200
• Fax: 415-875-7075
• Employees: 231
• Year Founded: 2005

Price Target and Rating

• Average Price Target for Capricor Therapeutics: $30.25
• High Price Target: $60.00
• Low Price Target: $2.00
• Potential Upside/Downside: +350.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.27
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$105.04 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -56.60%
• Return on Assets: -43.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.35
• Quick Ratio: 7.35

Sales & Book Value

• Annual Sales: $22.27 million
• Price / Sales: 17.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.53 per share
• Price / Book: 1.21

Miscellaneous

• Outstanding Shares: 58,140,000
• Free Float: 52,790,000
• Market Cap: $390.12 million
• Optionable: Optionable
• Beta: 0.61